ZBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zimmer Biomet Holdings, Inc. (ZBH) is not a strong buy for a beginner, long-term investor at this moment. The stock's technical indicators, options data, and financial performance suggest limited upside potential in the near term. Analysts have mixed to negative sentiment, and the company's recent financials show declining profitability despite revenue growth. Given the lack of strong positive catalysts and the absence of proprietary trading signals, holding off on this investment is advisable.
The MACD is slightly positive but contracting, RSI is neutral at 39.975, and moving averages are converging, indicating no clear trend. The stock is trading near its S1 support level of 92.047, with resistance at 94.487. Pre-market price is slightly down by -0.49%, suggesting weak momentum.
Citi raised the price target to $98, citing a beat on Q4 estimates. TD Cowen upgraded the stock to Buy with a $109 price target, highlighting improving growth and profit potential.
Analysts like BTIG and Barclays have downgraded or maintained negative ratings, citing limited product cycles and execution risks. Stock trend analysis indicates a high probability of short-term declines (-3.08% next day, -8.32% next week).
In Q4 2025, revenue increased to $2.24 billion (+10.90% YoY), but net income dropped to $139.3 million (-41.84% YoY). EPS fell to $0.70 (-41.67% YoY), and gross margin declined to 56.77% (-10.19% YoY), reflecting profitability challenges.
Analysts have mixed to negative ratings. Leerink and William Blair rated the stock Market Perform, while BTIG downgraded it to Neutral. Barclays maintains an Underweight rating, while UBS has a Sell rating. TD Cowen and Citi are more optimistic, with Buy ratings and higher price targets of $109 and $98, respectively.
